Latest American Association for Cancer Research Stories
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex.
An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as two days after therapy administration.
Charles J. Sherr, M.D., Ph.D., to receive the Prize for Scientific Excellence in Medicine by the American-Italian Cancer Foundation Memphis, Tenn.
- In medieval musical notation, a sign or neume denoting a shake or trill.